Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I am going to post some interesting items that I find in the 10Q....
As of April 2, 2016, the Company had approximately $2,996,000 cash and cash equivalents on hand. We anticipate that our current cash and cash equivalents on hand, and cash generated from operations will be sufficient to meet our projected operating plans through at least May 13, 2017. We may, however, seek additional capital prior to May 13, 2017, both to meet our projected operating plans after May 13, 2017 and/or to fund our longer term strategic objectives.
I am wondering how the new plant fits into their cash requirements. It will require cash outlay for its initial construction, startup and employees. However, I am sure that the savings on our costs of product will be well worth it.
Huge volume already. Going to be a good day. Tomorrow should be better because all the people at the conference who will hear our story will be joying us.
The 10Q makes for some great reading prior to the conference call.
GuguWei....I see this is your first post on our board. I hope you will stick around. I don't know what the high will be today, but I will say that the future looks very bright and that once we break out above $6.50, we could see $15.00. That's my longer term goal. JMO
ChromaDex Reports Record Revenue and Quarterly Net Income as Ingredients Sales Climb 72%
Company Records Net Income of $256,000 as Company Reports Record Revenue of $7.3 Million-
ChromaDex management will host an investor conference call to discuss the quarterly results and provide a general business update on Monday, May 16, at 11am EDT.
Participants should call in at least 10 minutes prior to the call. The dial-in information is as follows:
U.S. Toll-Free Number: (866) 327-8118
International Dial-In Number: (678) 509-7526
Conference ID: 10239097
The webcast replay will be available after the completion of the call on the Investor Relations section of the Company website, www.chromadex.com.
It appears to me that our CEO Frank Jaksch is going to be a very busy boy this Thursday....
Frank Jaksch, will present at the Drexel Hamilton Micro Cap Investor Forum. The investor forum will be held on May 12, 2016 at the offices of Drexel Hamilton in New York, New York.
Mr. Jaksch is scheduled to present on Thursday, May 12th at 9:00 a.m. Eastern Time. ChromaDex management will also be attending one-on-one meetings with institutional investors throughout the day.
PLUS...
CDXC announced today that it plans on reporting its first quarter 2016 financial results on Thursday, May 12, before the open of the financial markets.
ChromaDex management will host an investor conference call to discuss the quarterly results and provide a general business update on Monday, May 16, at 11am EDT.
NOW, would you want to report your financial results, while attending an investor forum, if the results for the quarter were not very positive?
ChromaDex to Report First Quarter 2016 Financial Results on Thursday, May 12, 2016
Company Will Host Investor Conference Call on Monday, May 16, 2016
IRVINE, Calif., May 10, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that it plans on reporting its first quarter 2016 financial results on Thursday, May 12, before the open of the financial markets.
ChromaDex management will host an investor conference call to discuss the quarterly results and provide a general business update on Monday, May 16, at 11am EDT.
Participants should call in at least 10 minutes prior to the call. The dial-in information is as follows:
U.S. Toll-Free Number: (866) 327-8118
International Dial-In Number: (678) 509-7526
Conference ID: 10239097
The webcast replay will be available after the completion of the call on the Investor Relations section of the Company website, www.chromadex.com.
The earnings press release, and its accompanying financial exhibits, will be available on the Investor Relations section of the Company website, www.chromadex.com.
Nice volume today. Highest in a long time. I hope this means some news is on the way.
Great find oldguy...the more exposure we get, the better for CDXC.
oldguy...looks like you were correct..
Is Elysium Health Basis a Hoax?
Basis uses Niagen supplied by Chromadex.
http://alivebynature.com/basis-niagen-by-elysium-health/
Excellent very technical site for NR information....
http://www.longecity.org/forum/topic/82770-nicotinamide-riboside-curated/page-15
Just found this...presentation on NR and weight loss - everyone is taking credit for discovering NR is some way...
https://events.unl.edu/2015/04/29/96768/
Just copied this off yahoo CDXC message board (I did not know that it even existed)
Chromadex patent app for skin anti aging Application number PCT/US2014/063260
This is why P&G is interested Who won't buy it if it reduces wrinkles ?
Institutional holdings...it appears CDXC is beginning to get noticed.
http://www.nasdaq.com/symbol/cdxc/institutional-holdings
I sent a message to the company yesterday regarding the Elysium Health article and the fact that they used the product names in the article without mentioning CDXC. I will post a copy of their reply if I get one.
starcig, please forgive my ignorance, but if we have the Intellectual property rights to NR, (are the rights given to persons over the creations of their minds. They usually give the creator an exclusive right over the use of his/her creation for a certain period of time) would'nt Elysium Health have to mention that as well on the product as well as the other group that was doing testing?
I have to say that I am a little confused after reading all the articles. CDXC only mentioned in one. And then this...
A new, high profile company with several Nobel Laureates on its board is the newest player to enter the anti-aging game. Elysium Health sells its supplement Basis online and as a subscription to combat aging. The two molecules in the current Basis formula, pterostilbene and nicotinamide riboside (NR), likely work by maintaining the health of mitochondria. One theory of aging proposes that these tiny energy factories in our cells are highly susceptible explains David Stipp at Scientific American:
I was looking at CDXC's PR's and did not find info on these researchers. Do we have a relationship with "Elysium Health" ?
WoW starcig..... great finds... all April 28,29. We should see the results of all those articles next week. Then we have the Drexel Hamilton Micro Cap Investor Forum on May 12, 2016. We should start to see the volume pick up and so should the PPS. Who ever was selling this week will regret it. Thanks
PR....ChromaDex to Present at the Drexel Hamilton Micro Cap Investor Forum on May 12, 2016
IRVINE, Calif., April 28, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness, and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today its Chief Executive Officer and Founder, Frank Jaksch, will present at the Drexel Hamilton Micro Cap Investor Forum. The investor forum will be held on May 12, 2016 at the offices of Drexel Hamilton in New York, New York.
Mr. Jaksch is scheduled to present on Thursday, May 12th at 9:00 a.m. Eastern Time. ChromaDex management will also be attending one-on-one meetings with institutional investors throughout the day.
If you would like to request a one-on-one meeting, please contact your Drexel Hamilton representative.
Normally I would say this is no big deal, but now I feel that it maybe the way to start getting some analysts to follow CDXC. That is a big deal now that we are listed.
About Drexel Hamilton:
Drexel Hamilton, LLC is a New York-based full-service institutional broker-dealer focused on capital markets, equities, corporate debt, government agencies, mortgages, and municipal finance. The firm was founded in 2007 on the principle of offering meaningful employment opportunities to disabled veterans desiring a career in financial services. With more than 90 professionals, including 42 military veterans, 24 of whom are service disabled, Drexel Hamilton has offices in Philadelphia, New York, Chicago, Jacksonville, Houston, Boston, Milwaukee, Lincoln, San Francisco, and Detroit. For more information, please visit our website at www.drexelhamilton.com.
Thanks finbin. If we stay down here tomorrow morning, I'll give it a shot.
I think this will provide a great buying opportunity. I will pick up more shares when I feel the short term bottom is in and the sellers are gone. My problem is the price seems to move back up so quickly that I would have to guess when the low is in.
Actually, I was NOT thinking that, which is a possibility, but my thoughts were that some flippers bought before the listing, knowing that the PPS would have to be above $4 for a period of time. That's just conjecture though. People sell for many reasons.
I hope the week hand or hands that have been selling are finally out of shares. The PPS of CDXC wants to go higher but they keep driving it lower.
It's good to see some of the long term holders post. I am trying to get some interest in Chromadex on IHUB. If you know of other shareholders, please have them post so I can update them when news breaks.
I think that now that we are listed and trading at a 4-5 dollar price, that analysts will start following the company. Then with some good news the PPS should really start to go much higher. JMO
ChromaDex to Begin Trading on The NASDAQ Capital Market Today
IRVINE, Calif., April 25, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), formerly (OTCQX:CDXC), an innovator of proprietary health, wellness, and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, today announced that the Company's common stock will be eligible to trade on The NASDAQ Capital Market under the symbol "CDXC" upon the open of the market today.
The NASDAQ Stock Market LLC approved the Company's application to have its common stock listed on The NASDAQ Capital Market by letter dated April 20, 2016.
Frank Jaksch Jr., founder and CEO of ChromaDex, commented, “The listing of our common stock on the NASDAQ will give ChromaDex greater visibility and stature in the financial community. It should also allow for increased sponsorship from intuitional investors, open doors to participate in investor conferences, and provide better overall liquidity for our stock. This graduation is in many ways a result of the remarkable progress the Company has made over the past two years."
More...and this ingredient could end up being huge for its blood pressure lowering ability.
We have also successfully conducted a clinical trial, together with the University of Mississippi, on our proprietary ingredient pterostilbene for its blood pressure lowering effects. We expect to conduct additional clinical trials on this compound and we anticipate entering the dietary
supplement and, if clinical results are favorable, possibly the pharmaceutical markets as well. We also have completed a study on our proprietary ingredient pterostilbene with caffeine co-crystal. The first human study of this ingredient demonstrated that it delivers 30 percent more caffeine,stays in the blood stream longer, and is absorbed more slowly than ordinary caffeine. We anticipate conducting additional clinical trials on NR and other compounds in our pipeline to provide differentiation as we market these proprietary ingredients and support various health-related
claims or obtain additional regulatory clearances.
Also from the annual report....
Manufacturing
For our ingredients segment and our core standards and contract services segment, we currently utilize third-party manufacturers to produce and
supply the ingredients. Following the receipt of products or product components from third-party manufacturers, we currently inspect products,
as needed. We expect to reserve the right to inspect and ensure conformance of each product and product component to our specifications. We will also consider manufacturing certain products or product components internally, if our capacity permits, when demand or quality requirements
make it appropriate to do so.
4ever_Trade
I think this will answer your question about the pilot plant. I took it from the annual report...
Process scale manufacturing. We intend to invest in a
pilot plant facility that has the capability of manufacturing at a process scale for products that we are planning to take to market
as well as explore cost saving processes for existing products.
Barchart.... http://www.barchart.com/opinions/stocks/CDXCD
Nice trading today...
Daily, weekly and monthly charts look great.
I am not sure how to answer your question except that the space
will serve as ChromaDex’s pilot plant facility. The company must have felt that sales of our products are such that opening a plant to produce them was necessary.
ChromaDex (OTCQX:CDXC) will begin trading on the Nasdaq Capital Market
on Monday, April 25. It will continue to trade on the OXTCQX under the symbol "CDXCD" until then.
Chromadex enters into lease for it's pilot plant facility....
Entry into a Material Definitive Agreement
On April 14, 2016, ChromaDex Analytics, Inc. (“ChromaDex”), a Nevada corporation and wholly owned subsidiary of ChromaDex Corporation, entered into a Lease Agreement (“Lease”), effective as of July 1, 2016, with Longmont Diagonal Investments LLC, a Delaware limited liability company (“Lessor”). Pursuant to the Lease, ChromaDex will rent approximately 10,052 square feet of office and laboratory space at 1751 South Fordham Street Suite #F, Longmont, CO 80503 (“Premises’), which will serve as ChromaDex’s pilot plant facility.
Press Release:
NECTAR7 Launches NIAGEN® & Collagen Dietary Supplement
IRVINE, Calif., April 19, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (OTCQX:CDXCD) (OTCQX:CDXC), an innovator of proprietary health, wellness, and nutritional ingredients, that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that NECTAR7 has released a new product, NIAGEN® & COLLAGEN featuring ChromaDex’s lead ingredient, NIAGEN®.
Jeromy Stallings, President of NECTAR7 Media commented, “NECTAR is excited about launching the first and only NIAGEN® & Collagen anti-aging nutricosmetic under the NECTAR7 brand. Most people are unaware that collagen production decreases approximately 1.5% per year starting around age 25. More importantly, science has shown that collagen production is NAD+ dependent. NIAGEN®, a major ingredient in the NECTAR7 exclusive formula, has been shown in a recent human trial to increase NAD+.” NECTAR7 nutricosmetics are available at www.NECTAR7.com.
Frank Jaksch Jr., founder and CEO of ChromaDex, commented, “We are proud to add NECTAR7 to the growing list of customers for NIAGEN®, our branded nicotinamide riboside.”
ChromaDex’s ingredient NIAGEN®, is the first and only commercially available form of nicotinamide riboside (NR), a naturally occurring vitamin B3 metabolite found in milk. In addition to human clinical studies, ChromaDex is actively collaborating with numerous leading universities and research institutes studying the health benefits of NIAGEN®.
In August 2015, ChromaDex announced results from the first human clinical study which demonstrated that a single dose of NIAGEN® can elevate the co-enzyme NAD+ in the blood by as much as 2.7-fold and was safe. The results of that study constituted a significant milestone as it showed for the first time an increase in NAD+ in humans has been demonstrated through NR supplementation.
About Nicotinamide Riboside (NR)
Published research has shown that NR is perhaps the most effective precursor to boost the co-enzyme NAD+ in the cell. NAD+ is arguably the most important cellular co-factor for improvement of mitochondrial performance and energy. In recent years, NAD+ has been shown to be essential in supporting healthy cellular metabolism, including the efficient conversion of blood glucose into energy.
As organisms age, NAD+ levels drop, which leads to a decrease in mitochondrial health; this in turn leads to age-related health issues. Low NAD+ levels limit activity of a group of enzymes called sirtuins, which are believed to play a key role in longevity. NAD+ levels can be depleted by lifestyle choices such as overeating and lack of exercise. By boosting NAD+, NR can increase mitochondrial health and induce creation of new mitochondria.
About NECTAR7:
NECTAR7, LLC is a global company that brings life-enhancing, science-based nutrition and lifestyle supplements to market. Its products are based on the latest scientific studies and breakthroughs. Backed by science and some of the world’s leading researchers, NECTAR7 markets performance-based nutritional supplements to help people improve healthspan. To learn more about NECTAR7, please visit https://www.nectar7.com/.
This is the link for the CDXCD monthly chart.
http://stockcharts.com/h-sc/ui?s=CDXCD&p=M&st=2008-04-01&en=today&id=p62838578244&a=446596373
Press release 4/13
Thorne Research Announces Clinical Study to Assess Nicotinamide Riboside on Brain NAD+ in College Football Players
- Mayo Clinic, University of Minnesota, and ChromaDex to Collaborate on Study -
IRVINE, Calif., April 13, 2016 (GLOBE NEWSWIRE) -- Thorne Research and ChromaDex Corp. (OTCQX:CDXC) announced today a research endeavor with Mayo Clinic and the University of Minnesota Clinical and Translational Science Institute, regarding a planned clinical study to assess the effect of Nicotinamide Riboside (NR) on brain NAD+ in college football players.
The randomized, placebo controlled, double-blind study will enroll healthy male collegiate football linemen, not having a history of more than 3 concussions. Participants will take either 750 mg per day of Nicotinamide Riboside (NR) or placebo for 84 days. Pre- and post-intervention evaluations include physical assessment, blood tests for safety and toxicity monitoring, blood tests for biomarkers, neurologic testing, quality of life questionnaires, and real time measurement of brain NAD, using 31P MRS.
The primary outcome of the study is to measure the change in brain NAD+ levels over 3 months. The study is expected to begin in May 2016 with final data collected by March 2017.
The study will utilize advanced 7 Tesla in vivo 31P Magnetic Resonance Spectroscopy (MRS) for noninvasive measurement of brain NAD+ concentrations, NAD+/NADH ratio, and ATP, using a method pioneered by Xiao-Hong Zhu, Ph.D., Associate Professor the University of Minnesota Center for Magnetic Resonance Research.
The principal investigators of the study are Dr. Zhu and Brent A Bauer, MD, Director of the Well Living Lab and Director of the Complementary and Integrative Medicine Program at Mayo Clinic in Rochester, Minnesota.
Paul Jacobson, the CEO of Thorne Research, stated, “We now have data showing that nicotinamide riboside raises NAD+ in the blood and in the brains of animals. We have further evidence that NR raises NAD+ in white blood cells and in plasma in humans. This will be the first trial to examine whether NR raises NAD+ in the brains of humans. Since concussion activates the DNA repair enzyme PARP-1 (which consumes and lowers NAD in the brain), the possibility that NR might raise brain NAD+ levels opens an exciting new frontier in how we might be able to manage football-related concussion and other forms of traumatic brain injury in the near future.”
Frank Jaksch Jr., founder and CEO of ChromaDex, commented “We are honored to collaborate with Dr. Zhu and Dr. Bauer and their respective research teams, as well as Thorne Research on this clinical trial. The human study is designed to provide a better understanding on how NR may affect brain NAD+ levels in athletes who participate in football and other contact sports.”
Thorne Research introduced NiaCel® in 2014, which features ChromaDex’s patented ingredient NIAGEN®, the first and only commercially available form of nicotinamide riboside (NR), a naturally occurring vitamin B3 metabolite found in milk.
ChromaDex, through more than 50 collaborations with researchers around the world, is in the forefront of research showing that the use of NR helps preserve or restore mitochondrial function and may be beneficial in treating and/or preventing disease.
CDXCD is going to need volume to break us out over the $6 and change resistance that has held it back for over 7 years but this year could be the year. We need the institutions to supply that volume.
2 sites I looked at today show zero% and .1% institutional ownership. Plenty of room to have that number increase and drive CDXCD much higher. JMO
My bad... I need to learn how to post a chart on the message board...
Click on "insert text here" and you should see the chart.